3.6669

2.90% 0.1169

Sana Biotechnology Inc (SANA)

Overview News Price History Option Chain Financials Why SANA Down? Discussions Forecast

Sana Biotechnology Inc stock is traded at $3.6669, with a volume of 1.08M. It is up +2.90% in the last 24 hours and up +15.97% over the past month. Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.

Previous Close:

$3.55

Open:

$3.52

24h Volume:

1.08M

Relative Volume:

0.30

Market Cap:

$1.10B

Revenue:

Net Income/Loss:

$-241.99M

P/E Ratio:

-3.9055

EPS:

-0.9389

Net Cash Flow:

$-133.64M

1W Performance:

+1.19%

1M Performance:

+15.97%

6M Performance:

-5.11%

1Y Performance:

+9.70%

1-Day Range:

$3.4655

$3.695

1-Week Range:

$3.365

$3.87

52-Week Range:

$2.61

$6.55

Sana Biotechnology Inc Stock (SANA) Company Profile

Name

Sana Biotechnology Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(206) 701-7914

Address

188 EAST BLAINE STREET, SUITE 350, SEATTLE

Employee

142

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

SANA's Discussions on Twitter

Compare SANA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SANA Sana Biotechnology Inc	3.675	1.06B	0	-241.99M	-133.64M	-0.9389
VRTX Vertex Pharmaceuticals Inc	515.67	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.59	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	993.07	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.47	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.63	39.31B	5.76B	514.49M	1.10B	4.4813

Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-24-25	Initiated	Wedbush	Outperform
Jul-03-25	Resumed	Morgan Stanley	Overweight
Mar-18-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Mar-14-25	Initiated	Jefferies	Buy
Jan-08-25	Upgrade	TD Cowen	Hold → Buy
Nov-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-26-24	Initiated	Rodman & Renshaw	Buy
Jan-16-24	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-25-23	Initiated	JMP Securities	Mkt Outperform
Sep-05-23	Initiated	Citigroup	Buy
Aug-14-23	Initiated	TD Cowen	Market Perform
May-02-23	Initiated	H.C. Wainwright	Neutral
Mar-01-21	Initiated	BofA Securities	Buy
Mar-01-21	Initiated	Goldman	Neutral
Mar-01-21	Initiated	JP Morgan	Neutral
Mar-01-21	Initiated	Morgan Stanley	Overweight

View All

Sana Biotechnology Inc Stock (SANA) Latest News

Aug 15, 2026

Sana Biotechnology (NASDAQ:SANA): Can Cell Therapy Drive the Next Chapter? - Kalkine Media

Aug 15, 2026

Aug 14, 2026

ARCH venture funds disclose 15%+ Sana Biotechnology (SANA) ownership in updated filing - Stock Titan

Aug 14, 2026

Sana Biotechnology | SCHEDULE 13G/A: Others - Moomoo

Aug 14, 2026

Bank of America Issues Pessimistic Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price - marketbeat.com

Aug 14, 2026

Sana Biotechnology (NASDAQ:SANA) Shares Down 5.3%Should You Sell? - marketbeat.com

Aug 14, 2026

Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.38, Implies 155% Upside - TradingView

Aug 14, 2026

BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7 - marketscreener.com

Aug 14, 2026

Aug 13, 2026

HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings - marketbeat.com

Aug 13, 2026

Aug 11, 2026

Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity DealWhat's Changed - webull.com

Aug 11, 2026

Sana Biotechnology: Insulin-Producing Cells Survive 14 Months Without Immunosuppression As Mayo Clinic Invests $25 Million - Pulse 2.0

Aug 11, 2026

Wedbush Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 11, 2026

SANA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Aug 11, 2026

Aug 10, 2026

Sana Biotechnology | 10-Q: Quarterly report - moomoo.com

Aug 10, 2026

Sana Biotechnology non-GAAP EPS beats estimate; cash runway extends to mid-2027 - scanx.trade

Aug 10, 2026

Sana Biotechnology falls 5% despite beating earnings estimates By Investing.com - Investing.com India

Aug 10, 2026

Sana Biotechnology falls 5% despite beating earnings estimates - Investing.com

Aug 10, 2026

Sana Biotechnology Q2 adjusted loss narrows, beats estimates - Bitget

Aug 10, 2026

Sana Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results - marketbeat.com

Aug 10, 2026

Sana Biotechnology Q2 Adjusted Loss Narrows - marketscreener.com

Aug 10, 2026

Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12 - marketscreener.com

Aug 10, 2026

Sana Biotechnology (SANA) warns on going concern amid $110.8M loss - stocktitan.net

Aug 10, 2026

Sana: Q2 Earnings Snapshot - KTVB

Aug 10, 2026

BRIEF-Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15 - TradingView

Aug 10, 2026

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates - Yahoo Finance

Aug 10, 2026

Aug 09, 2026

Sana Biotechnology faces earnings test as CAR-T program advances By Investing.com - Investing.com UK

Aug 09, 2026

Sana Biotechnology faces earnings test as CAR-T program advances - Investing.com

Aug 09, 2026

Aug 07, 2026